A phase I/II study to evaluate the safety, pharmacokinetics, and efficacy of PRJ1-3024 in patients with advanced solid tumors

被引：0
|
作者：
Zhang, Panpan
Qin, Yanru
Gong, Jifang
Wang, Yongsheng
Yang, Kunyu
Li, Yongsheng
Dai, Guanghai
Zhu, Ji
Sha, Sha
Tong, Ming
Liao, Xuebin
Shen, Lin
机构：
[1] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
[2] Zhengzhou Univ, Affiliated Hosital 1, Zhengzhou, Peoples R China
[3] Beijing Canc Hosp, Dept Gastrooncol, Beijing, Peoples R China
[4] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[5] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[6] Chongqing Canc Hosp, Chongqing, Peoples R China
[7] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[8] Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[9] Zhuhai Yufan Biotechnol Co Ltd, Zhuhai, Guangdong, Peoples R China
[10] Tsinghua Univ, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2590
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I trial to evaluate safety, pharmacokinetics, and efficacy of sorafenib combined with docetaxel in patients with advanced, refractory solid tumors
    Awada, A.
    Hendlisz, A.
    Whenham, N.
    Gil, T.
    Christensen, O.
    Lathia, C.
    Bartholomeus, S.
    Delabaye, I.
    De Valeriola, D.
    Brendel, E.
    Delaunoit, T.
    Piccart, M.
    ANNALS OF ONCOLOGY, 2007, 18 : 39 - 39
  • [2] A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors
    Puglisi, Martina
    Molife, L. Rhoda
    de Jonge, Maja J. A.
    Khan, Khurum H.
    Doorn, Leni van
    Forster, Martin D.
    Blanco, Montserrat
    Gutierrez, Martin
    Franklin, Catherine
    Busman, Todd
    Yang, Jianning
    Eskens, Ferry A. L. M.
    FUTURE ONCOLOGY, 2021, 17 (21) : 2747 - 2758
  • [3] A phase I/II, open-label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of HB0036 in patients with advanced solid tumors
    Sun, Yuping
    Yu, Jinming
    Tolcher, Anthony W.
    Albany, Costantine
    Chaudhry, Arvind
    Dang, Qi
    Ye, Leiguang
    Yang, Fang
    Liu, Baogang
    Sun, Longhua
    Tang, Jianjun
    Xu, Lei
    Zhu, Xiangyang
    Yang, Yongmin
    Yang, Yang
    Zhan, Yifan
    Li, Benke
    Hou, Kexin
    Zheng, Yang, Sr.
    Wang, Jingjing
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
    Sunakawa, Yu
    Furuse, Junji
    Okusaka, Takuji
    Ikeda, Masafumi
    Nagashima, Fumio
    Ueno, Hideki
    Mitsunaga, Shuichi
    Hashizume, Kensei
    Ito, Yuichiro
    Sasaki, Yasutsuna
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (01) : 104 - 112
  • [5] Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
    Yu Sunakawa
    Junji Furuse
    Takuji Okusaka
    Masafumi Ikeda
    Fumio Nagashima
    Hideki Ueno
    Shuichi Mitsunaga
    Kensei Hashizume
    Yuichiro Ito
    Yasutsuna Sasaki
    Investigational New Drugs, 2014, 32 : 104 - 112
  • [6] Evaluation of the safety, pharmacokinetics, and efficacy of JS']JSKN003 in patients with advanced solid tumors: A phase I/II clinical study.
    Liu, Xiaojun
    Zhang, Jian
    Shen, Lin
    Liu, Jieqiong
    Huang, Jian
    Zhuang, Zhixiang
    Yin, Yongmei
    Wang, Xiang
    Wang, Xian
    Wu, Jiong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
    Soria, J. -C.
    DeBraud, F.
    Bahleda, R.
    Adamo, B.
    Andre, F.
    Dientsmann, R.
    Delmonte, A.
    Cereda, R.
    Isaacson, J.
    Litten, J.
    Allen, A.
    Dubois, F.
    Saba, C.
    Robert, R.
    D'Incalci, M.
    Zucchetti, M.
    Camboni, M. G.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2014, 25 (11) : 2244 - 2251
  • [8] A phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
    Soria, Jean-Charles
    De Braud, Filippo G.
    Bahleda, Ratislav
    Adamo, Barbara
    Cereda, Roberta
    Camboni, Maria Gabriella
    Robert, Renate
    Isaacson, Jeffrey D.
    Litten, Jason B.
    Allen, Andrew R.
    Rolfe, Lindsey
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] A phase I study of safety and pharmacokinetics of NanoBB-1-Dox in patients with advanced solid tumors.
    Filon, Olga
    Krivorotko, Petr
    Kobyakov, Grigory
    Razjivina, Viktoria
    Maximenko, Olga
    Gelperina, Svetlana
    Kreuter, Joerg
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Erratum to: Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
    Yu Sunakawa
    Junji Furuse
    Takuji Okusaka
    Masafumi Ikeda
    Fumio Nagashima
    Hideki Ueno
    Shuichi Mitsunaga
    Kensei Hashizume
    Yuichiro Ito
    Yasutsuna Sasaki
    Investigational New Drugs, 2014, 32 : 388 - 388
12345